跳至主要内容
临床试验/NCT01766388
NCT01766388已完成不适用

Mifepristone and Misoprostol for Mid-trimester Termination of Pregnancy (13-22 Weeks LMP) in Armenia

Gynuity Health Projects2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
120
试验地点
2
主要终点
Rate of successful abortion

研究概览

简要总结

The primary goal of this study is to examine the efficacy and feasibility of a mifepristone combined with misoprostol medical abortion regimen in terminating pregnancies 13-22 weeks in Armenia.

详细描述

Women who were deemed eligible for the study by the provider gave informed consent. They took 200 mg of mifepristone orally at the study clinic. In 24-44 hours, they returned to the clinic for induction with misoprostol. They were admitted as inpatients at the clinic and took 400 mcg of buccal misoprostol every 3 hours until the fetus and placenta were expelled. If there was no full expulsion after 10 doses of misoprostol, the provider used their discretion to determine the appropriate clinical course of action. After responding to questions about their experience with the procedure, women were discharged from the study.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

性别
Female
接受健康志愿者

入选标准

  • Pregnancy of 13-22 weeks' gestation
  • Good general health
  • Meeting legal criteria to obtain abortion
  • Presenting with closed cervical os and no vaginal bleeding
  • Live fetus at time of presentation for service
  • Willingness to undergo a surgical completion if necessary
  • No contraindications to study procedures, according to provider
  • Woman willing and able to consent to procedure, either by reading consent document or by having consent document read to her
  • Willingness to follow study procedures

排除标准

  • Known previous transmural uterine incision
  • Known allergy to mifepristone or misoprostol/prostaglandin or other contraindications to the use of mifepristone or misoprostol
  • Parity greater than 5
  • Any contraindications to vaginal delivery, including placenta previa
  • Presentation in active labor (defined as moderate to severe contractions every 10 minutes or less)

结局指标

主要结局

Rate of successful abortion

时间窗: Every 3 hours after induction with misoprostol commences, up to 30 hours after the first dose

次要结局

  • Total dose of misoprostol(At the time of fetal and placental expulsion, up to 30 hours after the first dose)
  • Women's satisfaction with the method(At discharge, up to 5 days after enrollment)
  • Side effects(Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion or 30 hours after the first dose, whichever occurs first)
  • Women's acceptability of the side effects, buccal administration of misoprostol, and duration of procedure(At discharge, up to 5 days after enrollment)
  • Providers' acceptability of the method(After all study procedures complete, at close out, up to 1.5 years after study enrollment commences)
  • Complications including heavy bleeding, uterine rupture, or infection requiring additional treatment(Every 3 hours, starting from the first dose of misoprostol, up to fetal and placental expulsion, or 30 hours after the first dose, whichever occurs first)
  • Induction to fetal expulsion interval(Time from administration of first misoprostol dose to expulsion of the fetus, up to 30 hours after the first dose)
  • Induction to fetal and placental expulsion interval(Time from administration of first misoprostol dose to expulsion of the fetus and placenta, up to 30 hours after the first dose)

研究者

发起方
Gynuity Health Projects
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验